Is Solventum Corp. (SOLV) overvalued? · P/E 9.1, rev $8.25B
Solventum Corp. (SOLV) is a medical instruments & supplies company listed on NYSE.
This page asks whether Solventum Corp. (SOLV) looks expensive on cached numbers — not a short thesis.
Latest reported SOLV revenue for 2024-12-31 was $8.25B. Net income was $479.0M. Revenue was up 0.7% from 2023-12-31 to 2024-12-31. SOLV currently screens at market cap $12.91B and trailing P/E 9.1.
SOLV currently screens at market cap $12.91B and trailing P/E 9.1. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SOLV 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SOLV stock page for the full model, not this heading.
Not investment advice.